Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has reported a loss for its third fiscal quarter (ending June 30) of $-1.07 versus a loss $-1.86 for the same period a year ago. Relative to the consensus estimate of $-1.41, this was a premium of $0.34. For the latest four quarters through June 30, E.P.S. were $-5.45 compared to $-6.32 a year ago.
Recent Price Action
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) stock closed at $12.85 on 8/5/24 after a large decline of -7.6%. Trading volume in this decline was normal. The stock has declined -17.2% during the last week but has been exceptionally strong relative to the market over the last nine months.
Current PriceTarget Research Rating
ENTA is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Enanta Pharmaceuticals has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Enanta Pharmaceuticals has a very low Appreciation Score of 15 but a good Power Rating of 84, producing the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment